[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552725":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":11,"locations":28,"responsibleParty":36,"collaborators":11,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL",null,[13],"Drug: BMS-986435",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","BMS-986435","Specified dose on specified days",[9,15],[24],"MYK-224",[26],{"name":5,"affiliation":5,"role":27},"STUDY_DIRECTOR",[29],{"facility":30,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Local Institution - 0001","Xuhui District","Shanghai Municipality","200032","China","CN",{"type":37,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100552725","phase-1-a-study-to-evaluate-the-safety-tolerability-drug-levels-and-drug-effects-of-single-doses-of-bms-986435-myk-224-in-healthy-chinese-participants-100552725",false,"NCT06476821","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants","A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants","Inclusion Criteria:\n\n* Body weight of ≥ 50 kg and body mass index between 18.0 and 28.0 kg\u002Fm2, inclusive, at screening.\n* Participants must be Chinese (both biological parents are ethnically Chinese).\n* Participant has documented LVEF ≥ 60% (2D biplane Simpson's Method) at screening as determined by the echocardiographic core laboratory.\n\nExclusion Criteria:\n\n* Any acute or chronic medical illness.\n* Head injury in the last 2 years, intracranial tumor, or aneurysm.\n* History of malignancy of any type, except in situ cervical cancer \\> 5 years prior to the screening visit or surgically excised nonmelanomatous skin cancers \\> 2 years prior to the screening visit.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","60 Years",{"count":50,"type":51},20,"ACTUAL","INTERVENTIONAL",[54],"PHASE1","The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following a single oral dose of BMS-986435 in healthy adult Chinese participants.",[57],"Healthy Volunteers","COMPLETED","2024-11-16",{"date":61,"type":51},"2024-11-19",{"date":63,"type":51},"2024-06-27",{"date":65,"type":51},"2024-10-11",{"name":5,"class":6},1]